[ad_1]
Bagsværd, Denmark, 22 August 2022 – On three August 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Fee Delegated Regulation (EU) 2016/1052 of Eight March 2016 (the “Secure Harbour Guidelines”). This programme is a part of the general share repurchase programme of as much as DKK 24 billion to be executed throughout a 12-month interval starting 2 February 2022.
Below the programme initiated three August 2022, Novo Nordisk will repurchase B shares for an quantity as much as DKK 4.Four billion within the interval from Four August 2022 to 31 October 2022.
For the reason that announcement 15 August 2022, the next transactions have been made:
| Variety of B shares |
Common buy value |
Transaction worth, DKK |
|
| Gathered, final announcement | 635,000 | 488,903,671 | |
| 15 August 2022 | 90,000 | 777.71 | 69,994,189 |
| 16 August 2022 | 90,000 | 775.63 | 69,806,513 |
| 17 August 2022 | 90,000 | 775.45 | 69,790,447 |
| 18 August 2022 | 90,000 | 761.19 | 68,507,124 |
| 19 August 2022 | 90,000 | 771.29 | 69,416,024 |
| Gathered beneath the programme | 1,085,000 | 836,417,968 |
The small print for every transaction made beneath the share repurchase programme are revealed on novonordisk.com.
With the transactions said above, Novo Nordisk owns a complete of 18,703,211 B shares of DKK 0.20 as treasury shares, akin to 0.8% of the share capital. The full quantity of A and B shares within the firm is 2,280,000,000 together with treasury shares.
Novo Nordisk expects to repurchase B shares for an quantity as much as DKK 24 billion throughout a 12-month interval starting 2 February 2022. As of 19 August 2022, Novo Nordisk has since 2 February 2022 repurchased a complete of 16,992,432 B shares at a median share value of DKK 767.29 per B share equal to a transaction worth of DKK 13,038,186,830.
Novo Nordisk is a number one world healthcare firm, based in 1923 and headquartered in Denmark. Our objective is to drive change to defeat diabetes and different severe persistent illnesses reminiscent of weight problems and uncommon blood and endocrine problems. We achieve this by pioneering scientific breakthroughs, increasing entry to our medicines, and dealing to forestall and in the end remedy illness. Novo Nordisk employs about 47,800 folks in 80 international locations and markets its merchandise in round 170 international locations. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Inventory Alternate (NVO). For extra data, go to novonordisk.com, Fb, Twitter, LinkedIn, and YouTube.
Firm announcement No 67 / 2022
Additional data
[ad_2]
Supply hyperlink